Standard Biotools (LAB) Current Deferred Revenue (2010 - 2026)

Standard Biotools (LAB) has 17 years of Current Deferred Revenue data on file, last reported at $10.0 million in Q1 2026.

• Quarterly Current Deferred Revenue fell 21.8% year-over-year to $10.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.0 million (down 21.8% YoY) and the FY2025 annual result came in at $42.5 million, up 313.2% from the prior year.
• Current Deferred Revenue retreated to $10.0 million in Q1 2026 per LAB's latest filing, from $42.5 million in the prior quarter.
• Across five years, Current Deferred Revenue topped out at $48.5 million in Q2 2024 and bottomed at $10.0 million in Q1 2026.
• The 5-year median for Current Deferred Revenue is $15.5 million (2023), against an average of $22.7 million.
• The widest annual swing landed in 2022, when Current Deferred Revenue sank 44.35%; it then surged 313.2% in 2025.
• Tracing LAB's Current Deferred Revenue over 5 years: stood at $14.6 million in 2022, then decreased by 20.54% to $11.6 million in 2023, then decreased by 11.48% to $10.3 million in 2024, then surged by 313.2% to $42.5 million in 2025, then plunged by 76.49% to $10.0 million in 2026.
• Per Business Quant, the three latest LAB Current Deferred Revenue figures stand at $10.0 million (Q1 2026), $42.5 million (Q4 2025), and $42.5 million (Q3 2025).

Peer Comparison